Global hepatitis report 2017. World Health Organization. Geneva: 2017; p 83. Licence: CC BY-NC-SA 3.0 IGO. Available online: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed 02 June 2021.
Askarian M, Yadollahi M, Kuochak F, Danaei M, Vakili V, Momeni M. Precautions for health care workers to avoid hepatitis B and C virus infection. Int J Occup Environ Med. 2011;2(4):191–8.
CAS
PubMed
Google Scholar
Sarrazin C, Zimmermann T, Berg T, Neumann UP, Schirmacher P, Schmidt H, et al. Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-register-no.: 021/012. Zeitschrift fur Gastroenterologie. 2018;56(07):756–838. https://doi.org/10.1055/a-0599-1320.
Article
PubMed
Google Scholar
Zarębska-Michaluk D, Jaroszewicz J, Pabjan P, Łapiński TW, Mazur W, Krygier R, et al. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience? J Gastroenterol Hepatol. 2020;36(7):1944–52. https://doi.org/10.1111/jgh.15337.
Runge M, Krensel M, Westermann C, Bindl D, Nagels K, Augustin M, et al. Cost-effectiveness analysis of direct-acting antiviral agents for occupational hepatitis C infections in Germany. Int J Environ Res Public Health. 2020;17(2). https://doi.org/10.3390/ijerph17020440.
Westermann C, Peters C, Lisiak B, Lamberti M, Nienhaus A. The prevalence of hepatitis C among healthcare workers: a systematic review and meta-analysis. Occup Environ Med. 2015;72(12):880–8. https://doi.org/10.1136/oemed-2015-102879.
Article
PubMed
Google Scholar
Dulon M, Wendeler D, Nienhaus A. Berufsbedingte Infektionskrankheiten bei Beschäftigten im Gesundheitsdienst 2017. Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie. 2019;69:16–22. https://doi.org/10.1007/s40664-018-0307-4.
Article
Google Scholar
Westermann C, Dulon M, Wendeler D, Nienhaus A. Hepatitis C among healthcare personnel: secondary data analyses of costs and trends for hepatitis C infections with occupational causes. J Occup Med Toxicol. 2016;11(1):52. https://doi.org/10.1186/s12995-016-0142-5.
Article
PubMed
PubMed Central
Google Scholar
Westermann C, Wendeler D, Nienhaus A. Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents. J Occup Med Toxicol. 2018;13(1):16. https://doi.org/10.1186/s12995-018-0197-6.
Article
PubMed
PubMed Central
Google Scholar
Cohen J, Cohen P, West SG, Aiken LS. Applied multiple regression/correlation analysis for the behavioral sciences (3rd ed.). Mahwah: Lawrence. Erlbaum; 2003.
Google Scholar
Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir +/− ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/− ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther. 2016;44(4):400–10. https://doi.org/10.1111/apt.13696.
Article
CAS
PubMed
Google Scholar
Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453–64. https://doi.org/10.1016/s0140-6736(18)32111-1.
Article
CAS
PubMed
Google Scholar
Sarrazin C, Buggisch P, Mauss S, Müller T, Zimmermann T, Klinker H, et al. Evolution of HCV patient characteristics and DAA regimens in the German hepatitis C registry (DHC-R) in 2014 and 2015. Zeitschrift fur Gastroenterologie. 2019;57(05):584–92. https://doi.org/10.1055/a-0859-7561.
Article
PubMed
Google Scholar
Gonzalez-Grande R, Jimenez-Perez M, Gonzalez Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterology. 2016;22(4):1421–32. https://doi.org/10.3748/wjg.v22.i4.1421.
Article
CAS
Google Scholar
Nuno Solinis R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence. Infect Dis Ther. 2016;5(4):491–508. https://doi.org/10.1007/s40121-016-0134-x.
Article
PubMed
PubMed Central
Google Scholar
Stahmeyer JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Huppe D, et al. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial. J Viral Hepat. 2016;23(2):105–15. https://doi.org/10.1111/jvh.12471.
Article
CAS
PubMed
Google Scholar
Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016;36(6):817–26. https://doi.org/10.1111/liv.13071.
Article
CAS
PubMed
Google Scholar
Kalidindi Y, Jung J, Feldman R, Riley T III. Association of Direct-Acting Antiviral Treatment with Mortality among Medicare Beneficiaries with Hepatitis C. JAMA Netw Open. 2020;3(7):e2011055. https://doi.org/10.1001/jamanetworkopen.2020.11055.
Article
PubMed
PubMed Central
Google Scholar
Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010–2015. J Hepatol. 2017;67:15–22. https://doi.org/10.1016/j.jhep.2017.01.024.
Article
PubMed
Google Scholar
Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, et al. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology (Baltimore, Md.). 2018;68:1298–307. https://doi.org/10.1002/hep.30046.
Article
CAS
Google Scholar
Wörmann B. The treatment of hepatitis C- an introduction to the use of new medicines. Deutsches Arzteblatt Int. 2017;114:9–10. https://doi.org/10.3238/arztebl.2017.0009.
Article
Google Scholar
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–69. https://doi.org/10.1056/NEJMoa1702417.
Article
CAS
PubMed
Google Scholar
Schäfer M, Schwaiger M. Interferon-α-assoziierte psychische Nebenwirkungen. Fortschr Neurol Psychiatr. 2003;71(9):469–76. https://doi.org/10.1055/s-2003-42188.
Article
PubMed
Google Scholar
Slim J, Afridi MS. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV. Infect Dis Clin N Am. 2012;26(4):917–29. https://doi.org/10.1016/j.idc.2012.08.006.
Article
Google Scholar
Zeuzem S. Treatment options in hepatitis C. Deutsches Arzteblatt international. 2017;114:11–21. https://doi.org/10.3238/arztebl.2017.0011.
Article
PubMed
PubMed Central
Google Scholar
WHO global health sector strategy on viral hepatitis 2016–2021. Availabe online: http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1. Accessed 2 June 2021.
Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385(9973):1124–35. https://doi.org/10.1016/s0140-6736(14)62401-6.
Article
PubMed
PubMed Central
Google Scholar
Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, et al. Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-Monoinfected and HIV-HCV-Coinfected individuals: results from the German hepatitis C cohort (GECCO-01). Clin Infect Dis. 2016;63(10):1320–4. https://doi.org/10.1093/cid/ciw567.
Article
CAS
PubMed
Google Scholar